Réaction #11693

ord-d4ab1160d8704717bff53901854961c7

Conditions de réaction

Conditions détaillées
See reaction.notes.procedure_details.

Traitement

  1. 1
    Autreformed
  2. 2
    AutreThe solution was evaporated under vacuum
  3. 3
    workup.DISSOLUTIONthe residue was redissolved in ethyl acetate (100 mL)
  4. 4
    LavageThis was washed sequentially with 1.0 M aqueous hydrochloric acid (50 mL), 1.0 M aqueous sodium hydroxide (50 mL), water (50 mL) and brine (50 mL)
  5. 5
    Séchagedried over anhydrous sodium sulfate
  6. 6
    Autreevaporated under vacuum
  7. 7
    AutreThe resulting solid crude product was triturated with 20% methanol in diethyl ether (20 mL four times)
  8. 8
    AutreDrying under vacuum

Mode opératoire

(R)-4-amino-2, 3,4,5-tetrahydro-2-benzazepin-3 (1H)-one hydrochloride salt (387 mg) (amine free base prepared in U.S. Pat. No. 5,545,735) was added to a mixture of tetrahydrofuran (40 mL), 5-chloroindole-2-carboxylic acid (356 mg), 1-hydroxy-7-azabenzotriazole (272 mg), and 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (382 mg) at room temperature. Diisopropylethylamine (202 mg) was added, and the resulting yellow suspension was stirred under argon for 16 h, during which a solution formed. The solution was evaporated under vacuum and the residue was redissolved in ethyl acetate (100 mL). This was washed sequentially with 1.0 M aqueous hydrochloric acid (50 mL), 1.0 M aqueous sodium hydroxide (50 mL), water (50 mL) and brine (50 mL), dried over anhydrous sodium sulfate, and evaporated under vacuum. The resulting solid crude product was triturated with 20% methanol in diethyl ether (20 mL four times). Drying under vacuum provided pure title compound (283 mg). HPLC/MS [M+H]+, 354.

Source

DOI: 10.6084/m9.figshare.5104873.v1Brevet: US07098235B2uspto-grants-2006_08